✨ Free AI Report
Vetoquinol SA: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Vetoquinol SA
Company Research

Vetoquinol SA: Business Overview, Financials & Competitive Analysis

Vetoquinol SA scores 6/10 on the AskCyborg Cyborg Score (Solid). Vetoquinol offers stable cash generation in the defensive veterinary pharma sector with geographic diversification, but faces macro headwinds and commoditized market pressures limiting upside growth potential. Vetoquinol demonstrates stable operations with consistent €520M+ revenue, global distribution across 100+ countries, and presence in growing pet pharma segments. However, modest organic growth.

What is Vetoquinol SA's industry? Vetoquinol SA (vetoquinol.com) operates in Veterinary Pharmaceuticals. AskCyborg classifies Vetoquinol SA under Veterinary Pharmaceuticals in its company registry.

Vetoquinol is a France-based veterinary pharmaceutical company founded in 1933 that designs, develops, and sells veterinary drugs and non-medicinal products for livestock and companion animals across 100+ countries. T...

6/ 10Solid

Cyborg Score thesis

Vetoquinol offers stable cash generation in the defensive veterinary pharma sector with geographic diversification, but faces...

Read the full analyst-debate transcript →
Industry Veterinary Pharmaceuticals
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Vetoquinol SA Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Vetoquinol SA

AskCyborg analysts argue the bull and bear cases for Vetoquinol SA across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Vetoquinol SA OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Vetoquinol SA Overview

Pro stress-test →

Vetoquinol is a France-based veterinary pharmaceutical company founded in 1933 that designs, develops, and sells veterinary drugs and non-medicinal products for livestock and companion animals across 100+ countries. The company reported €526 million in annual sales for 2025, with 70% from companion animals (dogs, cats) and 30% from livestock (cattle, pigs).

Strategic Profile

Pro stress-test →

Vetoquinol operates as a diversified player in the global veterinary pharma market with products spanning pain/inflammation, antibiotics, anti-parasites, dermatology, cardiology, and behavior management. The company's geographic diversification—Europe 48.9%, North America 35.7%, Asia-Pacific 15.4%—and portfolio spanning 5 production sites globally provides operational resilience and market penetration advantages.

Competitive Landscape

Pro stress-test →

Vetoquinol competes in the global veterinary pharmaceuticals market alongside larger players like Zoetis (dominant global competitor) and regional competitors. The market is characterized by consolidation, with Vetoquinol maintaining mid-market positioning through specialized therapeutic portfolios and geographic reach.

Industry Context

Vetoquinol SA operates in Veterinary Pharmaceuticals.

Key facts

Founded: 1933 · Headquarters: Lure, France · Employees: ~2,000 · Revenue: €526M (2025) · Market cap: €922M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Vetoquinol SA.

  • Pet products represent 70% of sales—capturing tailwinds in premium pet healthcare spending and humanization of pet care
  • Essential Products segment grew 4.1% at constant exchange rates in 2025, demonstrating product portfolio resilience
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Monthly voting rights disclosure and buyback program announcements
  • February 20262025 annual results released with €526M revenue
  • +1 moreTrack every material event for Vetoquinol SA as it happens. Explore monitoring →
Get alerted when Vetoquinol SA has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Animal health divisionGlobal veterinary pharma leader and primary competitor→Veterinary pharmaceuticalsMajor animal health division competitor→Companion animal productsSignificant player in pet and livestock segments→

Compare Vetoquinol SA with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Vetoquinol SA operates in Veterinary Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Veterinary Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Vetoquinol SA

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Vetoquinol SA and its top competitor on Cyborg Score”
“What did Vetoquinol SA do this quarter?”
“Is Vetoquinol SA a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Vetoquinol SA do?+
Vetoquinol is a France-based veterinary pharmaceutical company founded in 1933 that designs, develops, and sells veterinary drugs and non-medicinal products for livestock and companion animals across 100+ countries. T...
What is Vetoquinol SA's Cyborg Score?+
Vetoquinol SA has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Vetoquinol SA's main competitors?+
Named competitors include Animal health division, Veterinary pharmaceuticals, Companion animal products. The full competitive landscape is in the AskCyborg report.
How can I get the full Vetoquinol SA research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Vetoquinol SA research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Vetoquinol SA over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.